TITLE

CLINIC ROUNDUP

PUB. DATE
August 2009
SOURCE
BioWorld Today;8/17/2009, Vol. 20 Issue 157, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on the biotechnology industry. Oxygen Biotherapeutics Inc. has received approval to start its Phase II, dose-escalation trial in Switzerland covering the use of Oxycyte in traumatic brain injury. DNage's investigational new drug application for Prodarsan has been approved by the U.S. Food & Drug Administration.
ACCESSION #
43758795

 

Related Articles

  • OTHER NEWS TO NOTE.  // BioWorld Today;3/19/2008, Vol. 19 Issue 54, p7 

    This section offers news briefs on the biopharmaceutical industry. The preclinical data for PEG-SN38 from Enzon Pharmaceuticals Inc. is published in the March 15, 2008, issue of the "Clinical Cancer Research." The U.S. Food and Drug Administration (FDA) has given milatuzumab from Immunomedics...

  • Clinic Roundup.  // BioWorld Today;6/5/2013, Vol. 24 Issue 107, p10 

    This section offers news briefs in the biotechnology industry. The U.S. Food and Drug Administration has granted permission to Kinex Pharmaceuticals INc. for the filing of an investigational new drug application for the drug KX02. The Phase I trial of NRX-1074 for the treatment of major...

  • Industry Pipeline.  // Ocular Surgery News;2/25/2014, Vol. 32 Issue 4, p37 

    The article offers news briefs relating to the ophthalmic business industry as of February 25, 2014. The European Medicines agency released marketing authorization for the preservative-free, single-dose formulation of Ganfort. Health Canada has approved the drug Jetrea for treating symptomatic...

  • Clinic Roundup.  // BioWorld Today;9/28/2010, Vol. 21 Issue 187, p2 

    This section offers news briefs on the biotechnology industry. An investigational new drug application for the LPA1 antagonist AM152 has been filed by Amira Pharmaceuticals Inc. to the U.S. Food and Drug Administration (FDA). Information on the findings of the Phase IV trial of Lexiscan...

  • Clinic Roundup.  // BioWorld Today;6/5/2013, Vol. 24 Issue 107, p8 

    This section offers clinical news briefs in the biotechnology industry. The U.S. Food and Drug Administration granted the Kinex Pharmaceuticals Inc. for the submission of an investigational new drug application for its KX02 drug. The Phase III trial of hGH-CTP product of Prolor Biotech Inc. has...

  • CLINIC ROUNDUP.  // BioWorld Today;9/11/2009, Vol. 20 Issue 175, p3 

    This section offers news briefs on the U.S. biotechnology industry. Preliminary results were reported by Acceleron Pharma Inc. from the ACE-031 Phase 1 single dose trial. An interim analysis of the safety and efficacy of Fampridine-SR for multiple sclerosis was presented by Acorda Therapeutics...

  • Other News To Note.  // BioWorld Today;3/4/2011, Vol. 22 Issue 43, p3 

    This section offers news briefs in the biotechnology industries. The Fond Unique Interministeriel has given 2 million euros to BioAlliance Pharma SA. Cell Therapeutics Inc. held a meeting with officials from the U.S. Food and Drug Administration (FDA) to discuss the rejection of a new drug...

  • FAST Act Would Provide Patients with Accelerated Access to Innovative Therapies.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article offers information related to Faster Access to Specialized Treatments (FAST) Act which helps in accelerating the approval process at the U.S. Food and Drug Administration. It further informs that this Act will enable biotech companies to bring new, safe and effective treatments and...

  • ED drugs in the pipeline.  // Contemporary Urology;Nov2001, Vol. 13 Issue 11, p54 

    The article provides an update on drug approval in the U.S. as of November 2001. A new drug application for vardenafil was recently submitted to the U.S. Food & Drug Administration (FDA) for approval. Phase III data demonstrated that 20 milligram of tadalafil improved erections in majority of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics